- The new PDUFA date is March 19, 2019
- The FDA has not requested any additional clinical data or any additional information from the Company as part of the extension
... read more
... read more
Inflazome, a pioneering inflammasome company developing small molecule drugs that block harmful inflammation, today announces the successful completion of a Series B financing round of €40 million... read more
Immunicum will initiate a study of ilixadencel in the fourth quarter of 2018. Following completion of the Ib portion of the study, a Phase II study will be conducted using the checkpoint inhibitor... read more
UCB, a global biopharmaceutical company working in Parkinson’s disease (PD) and other chronic illnesses, and Verint Systems Inc. (Nasdaq: VRNT), announced on 11/15/18 the release of UCB’s PD Coach... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,